Medline Inc

MDLN

Market cap $30.8B

New York, New York--(Newsfile Corp. - August 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

RADNOR, Pa., Aug. 7, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses.

New York, New York--(Newsfile Corp. - August 7, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Me.

Allspring Growth Fund outperformed the Russell 3000 Growth Index during the quarter. Sandisk Corp. is riding the AI storage super-cycle. Shares of Cencora could not distribute in a 'risk-on' market.

Medline Inc. (MDLN) Q2 2026 Earnings Call Transcript

Medline NASDAQ: MDLN reported second-quarter 2026 net sales growth of 12% to $7.7 billion, supported by demand across its medical-surgical product and supply-chain businesses, while raising its full-year organic sales outlook. The company also lowered its adjusted EBITDA guidance, citing operational investments, quality remediation efforts, retail weakness, Middle East-related inflation and costs associated with a June fire at its Tracy, California distribution center.

New York, New York--(Newsfile Corp. - August 5, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Although the revenue and EPS for Medline (MDLN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump, Omnipod, in the back half of the year.